Tsui Irena, Airiani Suzanna, Wen Angie, El-Sawy Tarek, Fine Howard F, Maris Peter J G
Department of Ophthalmology, Columbia University, New York, NY, USA.
Clin Ophthalmol. 2009;3:91-3. Epub 2009 Jun 2.
Implanting glaucoma tubes through the pars plana in the setting of a corneal transplant is becoming more common, and there are unique problems associated with such a procedure. A 42-year-old man with multiple previous eye surgeries presented with a nonfunctioning pars plana glaucoma tube. There was no view to the tube tip, but it was presumed to be clogged with fibrin. Intravitreal tissue plasminogen activator (tPA) was injected through the pars plana which resulted in intraocular pressure control without further surgery. This new application of intravitreal tPA has not been reported previously. Future research should investigate the optimal effective and safe dose of intravitreal tPA injection to relieve such occlusions.
在角膜移植手术中经睫状体扁平部植入青光眼引流管的情况越来越普遍,并且该手术存在一些独特的问题。一名有多次眼部手术史的42岁男性,其睫状体扁平部青光眼引流管失去功能。无法看到引流管尖端,但推测其被纤维蛋白堵塞。通过睫状体扁平部注射玻璃体内组织型纤溶酶原激活剂(tPA),眼压得到控制,无需进一步手术。玻璃体内tPA的这种新应用此前尚未见报道。未来的研究应探讨玻璃体内注射tPA以缓解此类阻塞的最佳有效和安全剂量。